I took that statement as an overall positive one. I would like to think that CTIX's frustration with trial speed is minimized compared to their appreciation of the benefits K got (and will continue to get) by having such a prestigious institution performing the initial work on the drug trial. I just think Leo is giving us the face value of the statement: the next trial(s) are going to proceed at a quicker speed, rather than at the extremely slow churn of academia. That's not to say they will be fast, but I am betting they will be no worse than the industry averages.